Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Rock_nj who wrote (4356)	3/17/1999 9:27:00 AM
From: Rande Is	Respond to of 57584

CYPB looks like the early morning winner. . . FDA approval for Prosorba Column [for rheumatoid arthritis] Bridge Technology Group reiterates a buy DOWNSIDE for any long-termers. . . The company reported a quarterly net loss applicable to common stockholders of approximately $2.2 million or $0.05 per share (basic and diluted) in 1998, versus a net loss of approximately $1.5 million or $0.04 per share (basic and diluted) for the comparable period in 1997. For the year ended Dec. 31, 1998, the company had a net loss applicable to common stockholders of approximately $11.2 million or $0.29 per share (basic and diluted), versus a net loss of approximately $8.9 million or $0.25 per share (basic and diluted) for the same period in 1997. Don't know much about this company or the trading of the stock, other than what is represented here. . . I have never owned it, nor do I currently own it. Rande Is